ProQR Therapeutics N.V. PRQR

PRQR Company Overview

ProQR Therapeutics N.V. is a clinical-stage biotechnology company focused on developing RNA-based therapeutics for rare diseases and other conditions with significant unmet medical needs. The company operates primarily within the biotechnology and pharmaceutical industries, with a strategic emphasis on RNA editing, RNA modulation, and precision genetic medicine. ProQR’s core technology platform, known as Axiomer, is designed to enable targeted RNA editing by modifying RNA molecules rather than permanently altering DNA, positioning the company within the broader field of next-generation genetic medicines.

The company was founded in 2012 in the Netherlands and initially concentrated on therapies for inherited retinal diseases. Over time, ProQR evolved from an ophthalmology-focused RNA therapy developer into a broader RNA-editing platform company following clinical and strategic reassessments of several earlier ophthalmology programs. Its primary value drivers now include platform licensing, research collaborations, and advancement of internally developed RNA-editing candidates. ProQR has sought to differentiate itself through its focus on reversible RNA editing technologies, which may offer advantages in specificity and safety compared with some permanent gene-editing approaches.